Aspire Biopharma Holdings (ASBP) Accumulated Expenses (2025 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly Accumulated Expenses came in at $441614.0 in Q1 2026, up 38.41% year-on-year from $319067.0 in Q1 2025, and down 56.21% on a QoQ basis from $1.0 million in Q4 2025.
Aspire Biopharma Holdings (ASBP) Accumulated Expenses (2025 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has 2 years of Accumulated Expenses data on file, last reported at $441614.0 in Q1 2026.
- On a quarterly basis, Accumulated Expenses rose 38.41% year-over-year to $441614.0 in Q1 2026; TTM through Mar 2026 was $441614.0, a 38.41% increase from a year earlier, with the FY2025 full-year figure at $1.0 million, changed N/A from the prior year.
- Accumulated Expenses for Q1 2026 stood at $441614.0, down from $1.0 million in the prior quarter.
- Over the last five years, Accumulated Expenses for ASBP reached as high as $1.0 million in Q4 2025 and fell as low as $266930.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Aspire Biopharma Holdings | 1.21 Mn | -619,284.29 | 5,750.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 441,614.00 |
| Dec 31, 2025 | 1.01 Mn |
| Sep 30, 2025 | 266,930.00 |
| Jun 30, 2025 | 378,181.00 |
| Mar 31, 2025 | 319,067.00 |